17. Molecular Basis of B-cell Lymphomas

  1. Hussain I. Saba MD, PHD2 and
  2. Ghulam J. Mufti MB, DM, FRCP, FRCPATH3
  1. Elizabeth M. Sagatys,
  2. Eduardo M. Sotomayor and
  3. Jianguo Tao

Published Online: 24 MAR 2011

DOI: 10.1002/9781444394016.ch17

Advances in Malignant Hematology

Advances in Malignant Hematology

How to Cite

Sagatys, E. M., Sotomayor, E. M. and Tao, J. (2011) Molecular Basis of B-cell Lymphomas, in Advances in Malignant Hematology (eds H. I. Saba and G. J. Mufti), Wiley-Blackwell, Oxford, UK. doi: 10.1002/9781444394016.ch17

Editor Information

  1. 2

    James A. Haley Veterans' Hospital, H. Lee Moffitt Cancer Center and Research Institute, University of South Florida College of Medicine, Tampa, FL, USA

  2. 3

    Department of Haematological Medicine, Guy's and St Thomas' School of Medicine, King's College Hospital, London, UK

Author Information

  1. Department of Oncological Sciences and Experimental Therapeutics Program, and Department of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA

Publication History

  1. Published Online: 24 MAR 2011
  2. Published Print: 16 APR 2011

ISBN Information

Print ISBN: 9781405196260

Online ISBN: 9781444394016



  • lymphomagenesis;
  • B-cell non-Hodgkin lymphomas;
  • cyclin D1;
  • c-myc;
  • Pax-5;
  • BCL-2;
  • BCL-6;
  • IRF4/MUM1;
  • BLIMP1


The past several years have witnessed a significant advancement in the elucidation of the molecular pathogenesis of tumors derived from B-lymphocytes. This progress has been the result of better understanding of the molecular basis of normal B-cell development from a progenitor B-cell to memory B-cell or plasma cell and how aberrations at these particular stages lead to a specific subtype of B-cell lymphoma displaying enhanced cell growth and proliferation, apoptosis inhibition and/or impaired differentiation. Here, we review the molecular principles of B-cell lymphomagenesis and how this knowledge is paving the way for the development of novel molecularly based therapeutic approaches for B-cell malignancies.